A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
Clinical trial NCT07038382 · RECRUITING
Trial details
- NCT number
- NCT07038382
- Sponsor
- Shanghai Henlius Biotech
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-05
- Primary completion
- 2027-01-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.